SARS-CoV-2 (COVID-19) Spike S1 Protein (RBD), liquid formulation Size:500µg resulting in the development of

resulting in the development of several autoimmune diseases

Cancer cells exploit the PD-1 pathway to evade immune surveillance

SARS-CoV-2 S1 (RBD) Omicron B

bioRxiv 2020

Recombinant protein of the receptor binding domain (RBD) of SARS-CoV-2 (COVID-2019) Spike S1 from Wuhan pneumonia virus

SARS-CoV-2 (COVID-19) Spike S1 Protein (RBD), liquid formulation Size:500µg resulting in the development ofRecombinant protein of the receptor binding domain (RBD) of SARS CoV 2 (COVID 19) Spike S1 from Wuhan pneumonia virus with C terminal His Tag, liquid formulation. Overview Product Name: SARS CoV 2 (COVID 19) Spike S1 Protein (RBD), liquid formulation Catalog No.: P2020 001 RefSeq Links: NC_045512. 2; MN908947. 3; YP_009724390. 1; QHD43416. 1; GeneID: 43740568; UniProt: P0DTC2 Synonyms: SARS CoV 2; coronavirus; SARS CoV 2 spike RBD; SARS CoV 2 spike